top of page
Our Portfolio
Our portfolio reflects the scale and diversity of the broader healthcare venture capital market.
For over 13 years, we have created customized solutions for venture funds, corporate venture funds, limited partnership interests, operating companies, and individual shareholders.

Torax Medical, Inc. develops and markets products designed to treat sphincter disorders utilizing its technology platform, Magnetic Sphincter Augmentation (MSA). It was acquired by Johnson & Johnson's Ethicon in 2017.

SurgiQuest Inc. develops, manufactures and markets innovative access technologies for minimally invasive surgery. It was acquired by ConMed in 2016.

Corventis is a pioneer in wearable, wireless technologies for cardiac disease. It was acquired by Medtronic in 2014.

Crescendo Bioscience develops diagnostic tools for rheumatologists to manage patients with autoimmune and inflammatory diseases. It was acquired by Myriad Genetics in 2014.

Pulsar Vascular Inc developed the PulseRider minimally invasive, self-expanding nitinol implant. It was acquired by Codman Neuro in 2016.

QuatRx is focused on development of therapeutics for endocrine and metabolic diseases. It was acquired by Shionogi Pharma Inc. in 2017.

Akebia is focused on the development of therapeutics based on hypoxia-inducible factor biology. IPO in 2014 (NASDAQ: AKBA).

NOVADAQ is a leading developer of fluorescence imaging technology. It was acquired by Stryker Corporation in 2017.

Esperion Therapeutics
focuses on the development of bempedoic acid. IPO in 2013 (NASDAQ: ESPR).

Aerpio Pharmaceuticals focuses on leveraging Tie2 activation for ocular disease and vascular stabilization. IPO in 2018 (NASDAQ: ARPO).

Counsyl is a health technology company that offers DNA screening for men, women, and their children. It was acquired by Myriad Genetics in 2018.

AcelRx Pharmaceuticals focuses on the development and commercialization of innovative therapies. IPO in 2011 (NASDAQ: ACRX).
bottom of page